Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 12/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.36 |
| ▸ | BRD1 | O95696 | 2/20 | 0.35 |
| ▸ | TAF1 | P21675 | 2/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889327 | 0.77 | MAPK13 (0.33) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2889325 | 0.77 | MAPK13 (0.33) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2889319 | 0.75 | GRM4 (0.43) | GRM4GRM1LMNASMN1; SMN2GRM7 | |
| SCHEMBL1837952 | 0.74 | GRM1 (0.42) | GRM4GRM1LMNASMN1; SMN2GRM7 | |
| SCHEMBL3327139 | 0.73 | GRM1 (0.40) | GRM4GRM1LMNASMN1; SMN2GRM7 | |
| SCHEMBL5429466 | 0.72 | GRM1 (0.51) | GRM4GRM1LMNASMN1; SMN2GRM7 | |
| SCHEMBL2884277 | 0.70 | GCK (0.41) | — | |
| SCHEMBL2887621 | 0.70 | GRM1 (0.46) | GRM4GRM1LMNASMN1; SMN2GRM7 | |
| SCHEMBL2889938 | 0.69 | HDAC6 (0.46) | GRM4GRM1GRM7 | |
| SCHEMBL11621300 | 0.69 | CYP3A4 (0.57) | GRM4GRM1LMNASMN1; SMN2GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130743-A1 | HETEROCYCLE-SUBSTITUTED, N-PHENYL-PHTHALAMIDE DERIVATIVES, RELATED COMPOUNDS AND THEIR USE AS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2010-05-27 | — | — | US | disclosed |
| US-7674807-B2 | Heterocycle-substituted n-phenyl-phthalamide derivatives, related compounds and their use as insecticides | BAYER CROPSCIENCE AG (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20070299085-A1 | N1-((Pyrazol-1-Ymethyl)-2-Methylphenyl)-Phatalamide Derivatives And Related Compounds Insecticides | BAYER CROPSCIENCE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1727804-A1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005095351-A1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130743-A1 | HETEROCYCLE-SUBSTITUTED, N-PHENYL-PHTHALAMIDE DERIVATIVES, RELATED COMPOUNDS AND THEIR USE AS INSECTICIDES | DDT, SQOR, CYP2S1 | GRM4 3253/4885GRM1 1638/4885LMNA 1336/4885 |
| US-20070299085-A1 | N1-((Pyrazol-1-Ymethyl)-2-Methylphenyl)-Phatalamide Derivatives And Related Compounds Insecticides | CHRM1, KCNH1, DDT | GRM4 3860/4885GRM1 1863/4885LMNA 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.